68-5

98/120

) Hamamichi S, Fukuhara T, Hattori N: Immu‑notoxin Screening System: A rapid and direct approach to obtain functional antibodies with internalization capacities. Toxins, 2020; 12: 1-15.) Kamagata K, Andica C, Hatano T, Ogawa T, Takeshige-Amano H, Ogaki K, Akashi T, Hagiwara A, Fujita S, Aoki S: Advanced diffusion magnetic resonance imaging in 548Japanese patients with Parkinson’s disease: A multicenter cross-sectional study. J Neurol Sci, 2020; 412: 116641. 86) Tsuboi Y, Hattori N, Yamamoto A, Sasagawa Y, Nomoto M: ME2125-4 Study Group. Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japa‑nese patients with Parkinson’s disease with wearing-off: Results of an open-label study. J Neurol Sci, 2020; 416: 117012. doi:10.1016/j.jns.2020.117012. Epub 2020 Jul 6. PMID: 32673884. 87) Tsunemi T, Ishiguro Y, Yoroisaka A, Valdez C, Miyamoto K, Ishikawa K, Saiki S, Akamatsu W, Hattori N, Krainc D: Astrocytes Protect Human Dopaminergic Neurons from α-Synu‑clein Accumulation and Propagation. J Neurosci, 2020; 40: 8618-8628. doi: 10.1523/JNEUROSCI.0954-20.2020. Epub 2020 Oct 12. PMID:33046546; PMCID: PMC7643299.＊ 88) Ueno SI, Hatano T, Okuzumi A, Saiki S, Oji Y, Mori A, Koinuma T, Fujimaki M, Takeshige-Amano H, Kondo A, Yoshikawa N, Nojiri T, Kurano M, Yasukawa K, Yatomi Y, Ikeda H, Hattori N: Nonmercaptalbumin as an oxida‑tive stress marker in Parkinson’s and PARK2 disease. Ann Clin Transl Neurol, 2020; 7: 307-317. doi: 10.1002/acn3.50990. 89) Ueno SI, Oyama G, Kanai K, Hatano T, Shimo Y, Hattori N: A Retrospective Imaging Eval‑uation of Presynaptic Dopaminergic Degen‑eration in Multiple System Atrophy with Levodopa Induced Dyskinesia. Tremor Other Hyperkinet Mov (N Y), 2020; 10: 6. doi: 10. 5334/tohm.58. 90) Ueno Y, Hira K, Miyamoto N, Kijima C, Inaba T, Hattori N: Pleiotropic Effects of Exosomes as a Therapy for Stroke Recovery. Int J Mol Sci, 2020; 21: 6894. doi: 10.3390/ijms21186894. PMID: 32962207; PMCID: PMC7555640. 91) Watanabe H, Saiki H, Chiu SW, Yamaguchi T, Kashihara K, Tsuboi Y, Nomoto M, Hattori N, Maeda T, Shimo Y; J‐FIRST Group: Real-World Nonmotor Changes in Patients with Parkinson’s Disease and Motor Fluctuations: J-FIRST. Mov Disord Clin Pract, 2020; 7: 431-439. doi: 10.1002/mdc3.12939. 92) Yamaguchi A, Ishikawa KI, Inoshita T, Shiba-Fukushima K, Saiki S, Hatano T, Mori A, Oji Y, Okuzumi A, Li Y, Funayama M, Imai Y, Hattori N, Akamatsu W: Identifying Thera‑peutic Agents for Amelioration of Mitochon‑drial Clearance Disorder in Neurons of Familial Parkinson Disease. Stem Cell Reports, 2020; 14: 1060-1075. doi: 10.1016/j.stemcr.2020.04.011. 93) Yamanaka T, Miyazaki H, Tosaki A, Maity SN, Shimogori T, Hattori N, Nukina N: Gene expression profiling in neuronal cells identi‑fies a different type of transcriptome modu‑lated by NF-Y. Sci Rep, 2020; 10: 21714. doi:10.1038/s41598-020-78682-8. 94) Yamashiro K, Tanaka R, Kurita N, Ueno Y, Miyamoto N, Hira K, Nakajima S, Urabe T, Hattori N: Cerebral Microbleeds and Chronic Kidney Disease in Acute Ischemic Stroke Patients with Atrial Fibrillation. J Stroke Cerebrovasc Dis, 2020; 29: 104650. doi: 10. 1016/j.jstrokecerebrovasdis.2020.104650. 95) Yamashita Y, Hatano T, Ogawa T, Daida K, Motoi Y, Hattori N: Steroid-Responsive Parkin‑sonism Caused by Cerebral Amyloid Angiop‑athy-Related Inflammation. Mov Disord Clin Pract, 2020; 7: 329-331. doi:10.1002/mdc3.12901. 96) Yoritaka A, Shimo Y, Hatano T, Hattori N: Motor/Nonmotor Symptoms and Progression in Patients with Parkinson’s Disease: Preva‑lence and Risks in a Longitudinal Study. Parkinsons Dis, 2020; 2020: 2735361. doi:10. 1155/2020/2735361. 97) Zhang C, Ramirez-Zamora A, Meng F, Lin Z, Lai Y, Li D, Chang J, Morishita T, Inoue T, Fujioka S, Oyama G, Coyne T, Voon V, Doshi PK, Wu Y, Liu J, Patel B, Almeida L, Wagle Shukla AA, Hu W, Foote K, Zhang J, Sun B, Okun MS: An International Survey of Deep Brain Stimulation Utilization in Asia and Oceania: The DBS Think Tank East. Fron‑tiers in human neuroscience, 2020; 14: 162.〈Reviews〉 1 2